Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trilogy International Partners Inc T.TRL.WT.A


Primary Symbol: V.TRL.H

Trilogy International Partners Inc. operates through its subsidiary Trilogy International Partners LLC (Trilogy LLC). Prior to the disposal of its New Zealand and Bolivia operations, Trilogy LLC was a provider of wireless voice and data communications services including local, international long distance and roaming services. Trilogy LLC also provided fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia. The Company had two reportable segments identified by their geographic regions, New Zealand and Bolivia. Two Degrees Mobile Limited (2degrees) operated in New Zealand and Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A. (NuevaTel) operated in Bolivia. Both these segments provided a variety of wireless voice and data communications services, including local, international long distance and roaming services. The services were provided to subscribers on both a postpaid and prepaid basis.


TSXV:TRL.H - Post by User

Comment by LTOWNERon Feb 01, 2014 4:22pm
121 Views
Post# 22162420

RE:Nature got it right

RE:Nature got it rightAbsolutely Knoll.  Men and women all produce testosterone naturally and the testosterone used in T-Replacement is bioidentical (unlike the estrogen from pregnant mares given to women).  TID Compleo may benefit further because low doses of testosterone are evenly distributed throughout the day.
 
To answer my own question as to why legitimate researchers would bother with a non-random study, it may be to get attention on controversial subjects, or a publish or perish thing.  The media loves these articles.  When one compares the length to which researchers go to get drug approvals – phase I, II,&  III trials and safety studies – there is no comparison.  The study in question was published in PLOS ONE, an ‘open access’ journal avoided by many because there is considerable negative bias against such journals, criticized “both for their lack of sub-editorial services and for creating a home for poor quality science …It also seems like PLoS has become a 'last resort' place to publish for people who get frustrated by the reviewing process or rejection by 'higher' impact journals … “PLoS ONE is falling short of what it could be because it was founded by Science 1%ers who are clueless and out of touch … a licence to pollute the literature with low-grade science” – just some of the negative comments on the Web about the publication although there is no doubt a place for open access journals and many of the articles will prove sound.
 
In the 70’s & 80’s studies came out concerned that vasectomy may cause cancer, arthritis, heart and blood vessel disease.  The media ran headlines to this effect at a time when the procedure was gaining popularity.  Many years later, these concerns have been put to rest.  It can take decades to know the long term effects of drugs.

Bullboard Posts